1. Home
  2. ENTA vs FRAF Comparison

ENTA vs FRAF Comparison

Compare ENTA & FRAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • FRAF
  • Stock Information
  • Founded
  • ENTA 1995
  • FRAF 1906
  • Country
  • ENTA United States
  • FRAF United States
  • Employees
  • ENTA N/A
  • FRAF N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • FRAF Major Banks
  • Sector
  • ENTA Health Care
  • FRAF Finance
  • Exchange
  • ENTA Nasdaq
  • FRAF Nasdaq
  • Market Cap
  • ENTA 160.3M
  • FRAF 152.9M
  • IPO Year
  • ENTA 2013
  • FRAF N/A
  • Fundamental
  • Price
  • ENTA $7.89
  • FRAF $37.06
  • Analyst Decision
  • ENTA Buy
  • FRAF
  • Analyst Count
  • ENTA 4
  • FRAF 0
  • Target Price
  • ENTA $18.00
  • FRAF N/A
  • AVG Volume (30 Days)
  • ENTA 181.3K
  • FRAF 49.4K
  • Earning Date
  • ENTA 08-04-2025
  • FRAF 07-22-2025
  • Dividend Yield
  • ENTA N/A
  • FRAF 3.56%
  • EPS Growth
  • ENTA N/A
  • FRAF N/A
  • EPS
  • ENTA N/A
  • FRAF 2.62
  • Revenue
  • ENTA $64,462,999.00
  • FRAF $71,310,000.00
  • Revenue This Year
  • ENTA N/A
  • FRAF N/A
  • Revenue Next Year
  • ENTA $0.48
  • FRAF N/A
  • P/E Ratio
  • ENTA N/A
  • FRAF $14.13
  • Revenue Growth
  • ENTA N/A
  • FRAF 5.61
  • 52 Week Low
  • ENTA $4.09
  • FRAF $27.00
  • 52 Week High
  • ENTA $17.24
  • FRAF $40.76
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 67.33
  • FRAF 61.19
  • Support Level
  • ENTA $6.95
  • FRAF $33.87
  • Resistance Level
  • ENTA $8.23
  • FRAF $35.42
  • Average True Range (ATR)
  • ENTA 0.40
  • FRAF 0.96
  • MACD
  • ENTA 0.00
  • FRAF 0.34
  • Stochastic Oscillator
  • ENTA 75.11
  • FRAF 93.78

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About FRAF Franklin Financial Services Corporation

Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.

Share on Social Networks: